Cost comparison of prostaglandin analogues: a Canadian population-based analysis

References

• Quigley H. Number of people with glaucoma worldwide. British Journal of Ophthalmology 1996; 80: 389–393.
   PubMed Web of Science ®Google Scholar
• Fuchs J, Nissen K, Goldschmidt E. Glaucoma blindness in Denmark. Acta Ophthalmologica (Copenhagan) 1992; 70((1))73–78.
   Google Scholar
• American Academy of Ophthalmology. Primary Open-Angle Glaucoma. American Academy of Ophthalmology, San FranciscoCA 2000.
   Google Scholar
• Collaborative normal-tension glaucoma study group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. American Journal of Ophthalmology 1998; 126((4))498–505.
   Google Scholar
• The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. American Journal of Ophthalmology 2000; 130((4))429–440.
   Google Scholar
• Gordon M, Beiser J, Brandt J, et al. The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Archives of Ophthalmology 2002; 120((6))714–720.
   Google Scholar
• Leske M, Heijl A, Hussein M, et al. Factors for glaucoma progressioni and the effect of treatment. The early manifest glaucoma trial. Archives of Ophthalmology 2003; 121((1))48–56.
   Google Scholar
• Lichter P, Musch D, Gillespie B, et al. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. American Journal of Ophthalmology 2001; 108((11))1943–1953.
   Google Scholar
• Soltau J, Zimmerman T. Changing paradigms in the medical treatment of glaucoma. Survey of Ophthalmology 2002; 47((Suppl 1))S2–S5.
   Google Scholar
• Leske M, Connell A, Schachat A, et al. The Barbados eye study: prevalence of open angle glaucoma. Archives of Ophthalmology 1994; 112: 821–829.
   PubMed Web of Science ®Google Scholar
• Alward W. Medical management of glaucoma. The New England Journal of Medicine 1998; 339((18))1298–1307.
   Google Scholar
• Coleman A. Glaucoma. Lancet 1999; 354: 1803–1810.
   PubMed Web of Science ®Google Scholar
• Schuman J. Antiglaucoma medications: a review of safety and tolerability issued related to their use. Clinical Therapeutics 2000; 22((2))167–208.
   Google Scholar
• Schwartz K, Budenz D. Current management of glaucoma. Current Opinion in Ophthalmology 2004; 15((2))119–126.
   Google Scholar
• Sherwood M, Migdal C, Hitchings R, et al. Initial treatment of glaucoma: surgery or medications. Survey of Ophthalmology 1993; 37((4))293–305.
   Google Scholar
• Health Canada. Notice of Compliance Database. Health Canada; 2006. http://www.nocdatabase.ca Last Updated 13th June 2005. Accessed 5th May 2006.
   Google Scholar
• Alexander C, Miller S, Abel S. Prostaglandin analogue treatment of glaucoma and ocular hypertension. The Annals of Pharmacotherapy 2002; 36((3))504–511.
   Google Scholar
• Camras C, Toris C, Tamesis R. Efficacy and adverse effects of medications used in the treatment of glaucoma. Drugs & Aging 1999; 15((5))377–388.
   Google Scholar
• Nguyen Q. The role of prostaglandin analogues in the treatment of glaucoma in the 21st century. International Ophthalmology Clinics 2004; 44((2))15–27.
   Google Scholar
• Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. Journal of Clinical Epidemiology 1995; 48((8))999–1009.
   Google Scholar
• CPS. Compendium of Pharmaceuticals and Specialties (CPS). The Canadian Drug Reference for Health Professionals. Canadian Pharmacists Association, OttawaON 2006
   Google Scholar
• Health Canada. Notice of Compliance: Lumigan. Ottawa, ON: Health Canada; 2006. http://www.nocdatabase.ca Last Updated 13th June 2005. Accessed 5th May 2006.
   Google Scholar
• CPS. Compendium of Pharmaceuticals and Specialties. Travatan (Travoprost). Elevated Intraocular Pressure Therapy – Prostaglandin F2a Analogue. Canadian Pharmacists Association, OttawaON 2006.
   Google Scholar
• CPS. Compendium of Pharmaceuticals and Specialties. Xalatan (Latanoprost). Elevated Intraocular Pressure Therapy – Prostaglandin F2a Analogue. Canadian Pharmacists Association, OttawaON 2006.
   Google Scholar
• CPS. Compendium of Pharmaceuticals and Specialties. Limigan (Bimatoprost). Elevated Intraocular Pressure Therapy – Prostaglandin F2a Analogue. Canadian Pharmacists Association, OttawaON 2006.
   Google Scholar
• Iskedjian M, Walker J, Vicente C, et al. Cost of glaucoma in Canada: analyses based on visual field and physician's assessment. Journal of Glaucoma 2003; 12((6))456–462.
   Google Scholar
• Lachaine J, Hodge W, Steffensen I, et al. Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis. Canadian Journal of Ophthalmology February, 2008; 43((1))33–41.
   Google Scholar
• Schwartz G, Mozaffari E, Oates V, et al. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. American Journal of Managed Care 2002; 8((Suppl))S255–S261.
   Google Scholar
• Wilensky J, Fiscella R, Carlson A, et al. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. American Journal of Ophthalmology 2006; 141((1 Suppl))S28–S33.
   Google Scholar
• Covert D, Robin A. Adjunctive glaucoma therapy use associated with travoprost, bimatroprost and latanoprost. Current Medical Research and Opinion 2006; 22((5))971–976.
   Google Scholar